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Abstract 
 
Varicella zoster virus (VZV) is the etiologic agent of chickenpox (varicella) upon primary 
infection and shingles (herpes zoster, HZ) upon reactivation from neuronal latency.  Shingles is a 
debilitating disease of the elderly and immune impaired that is frequently complicated. 
Reactivation of VZV causing HZ is painful and can result in a chronic pain state known as 
postherpetic neuralgia (PHN) that is difficult to alleviate.  HZ has also been linked to encephalitis, 
meningitis, vasculopathies and increased risk of stroke, all of which emphasize the continued 
public health demand for better treatments and/or vaccines.  VZV latency and reactivation has not 
been well characterized because it presents monumental difficulties studying it in a laboratory 
setting.  Its human-specific restriction requires human neuronal platforms for modeling 
neurotropism, latency and reactivation.  Importantly, VZV genomes are found not only in neurons 
of sensory ganglia, but in those of autonomic, enteric and cranial ganglia, and possibly even the 
CNS.  These latent genomes are difficult to characterize and are usually found only by performing 
end-stage methods of analyses, when tissues/cells need to be fixed or extracted.  One aspect of this 
research was to explore methods that would better enable the identification of VZV genomes in 
latently infected cells and whether they could be applied in a live-cell in vitro setting.  We have 
previously established that sensory-like neurons derived from human embryonic stem cells (hESC) 
can host both a productive VZV infection and a model state of VZV latency that can be 
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experimentally reactivated.  However, the maintenance of hESCs and their differentiation into 
sensory neurons for larger scale applications is exceedingly demanding.  The second goal of this 
research was to evaluate an alternative neuron-like system that is more easily expandable for large-
scale applications.  We evaluated the proliferative human neuronal precursor cell line Lund human 
mesencephalic (LUHMES) cells.  Differentiated LUHMES can easily be scaled to large numbers 
and show biochemical, morphological, and functional features of mature neurons.  While both 
undifferentiated and differentiated LUHMES cells are fully permissive to VZV infection, current 
studies are addressing the potential of this system to host a VZV latent state, and whether this is 
experimentally reactivatable.   
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 Introduction 
1.1 Varicella-Zoster Virus 
Varicella-zoster virus (VZV) causes varicella (chickenpox) upon primary infection and 
herpes-zoster (shingles) following reactivation from neuronal latency.  VZV is highly 
communicable through aerosolized respiratory droplets containing virus or direct contact with skin 
lesions of an infected individual [1].  Varicella is characterized as an acute, highly contagious 
disease which presents clinical symptoms following an incubation period of 10-21 days after 
acquisition [2].  Clinical symptoms associated with varicella include headache, fever, malaise, and 
a characteristic itchy vesicular rash.  VZV gains access to sensory neurons innervating the skin 
and travels by retrograde axonal transport to the sensory ganglia where it establishes a quiescent, 
or latent, state for the life of the host [3].  Since the virus has a T-cell-mediated systemic phase 
during varicella, it has been strongly suggested that this permits the virus to gain access to multiple 
non-sensory ganglia and even the enteric nervous system [4, 5].  VZV can reactivate from this 
latent state due to immunosenescence or immunodeficiency to cause a reactivated infection known 
as herpes-zoster (HZ).  During reactivation, the virus replicates within neurons and spreads to other 
neurons within the same ganglia.  The virus then travels by anterograde axonal transport along the 
nerve fibers innervating the skin to cause a dermatomal vesicular rash.  HZ clinical symptoms 
manifest as radicular pain, itching, increased sensitivity to stimuli causing pain (hyperalgesia), and 
hypersensitivity to touch (mechanical allodynia) and heat (thermal hyperalgesia).  Although the 
disease resolves within 7-20 days, 10-30% of individuals may experience a persistent debilitating 
pain state known as postherpetic neuralgia (PHN), which can last for months to decades.  Herpes 
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zoster ophthalmicus (HZO) occurs when a reactivation event occurs in the ophthalmic branch of 
the trigeminal ganglia.  HZO presents as a dermatomal rash on the forehead and can affect any 
part of the eye from the conjunctiva to the optic nerve [6]. 
Live-attenuated vaccines are available for both varicella and herpes zoster, Varivax and 
Zostavax, respectively.  Both were made from the same attenuated Oka strain of VZV by serial 
passaging in guinea pig embryo fibroblasts and then human cell lines.  The well-tolerated and 
highly efficacious varicella vaccine has proven to be 70-90% protective against infection and 90-
100% effective against preventing moderate and severe disease [7].  Zostavax contains around 14-
fold higher titer of the same Oka strain used in the varicella vaccine.  This HZ vaccine has shown 
to provide a reduction of about 51% in the development of shingles and about a 67% reduction in 
the development of PHN (measured as the “burden of disease”), but protection appears short lived 
for only 4-8 years from vaccination [8].  A recent development has been a subunit vaccine, 
Shingrix, for HZ that has proven to be more than 90% effective at preventing both shingles and 
PHN.  Initial studies suggest it maintains a longer efficacy of protection around 85% protection 
for at least 4 years [9, 10].  Despite the availability of these vaccines, HZ vaccination coverage is 
still rather low due to a variety of reasons, with one being a lack of knowledge regarding the 
possible severity of HZ.  This large percentage of the population that remains unvaccinated 
continue to be at risk for reactivation of wild-type VZV, possible vaccine breakthrough infections, 
and/or even vaccine-induced HZ.  This emphasizes the continued public health concern for VZV.  
1.1.1  VZV virology 
VZV is a member of the alphaherpesvirinae subfamily of the Herpesviridae family.  VZV 
has a double-stranded DNA (dsDNA) genome of 125-kilobase pairs that contains at least 70 unique 
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open reading frames, or ORFs, of which 5 have no homologs to other herpesviruses [11].  VZV 
gene expression kinetics are assumed to mirror those of other alphaherpesviruses, such as HSV 
and pseudorabies virus (PRV), in which immediate early (IE) genes are expressed first in the 
absence of de novo viral protein synthesis.   Early (E) genes are transcribed following accumulation 
of functional IE gene products.  Finally, late (L) genes are maximally transcribed only after DNA 
replication, with some being made at low levels before (L1) and others absolutely requiring DNA 
replication to start (L2).  However, because the virus is extraordinarily cell-associated in in vitro 
culture, it is difficult to obtain high titers of cell-free infectious virus, making it very difficult to 
experimentally prove this.   
Structurally the virus resembles that of other herpesviruses.  The linear dsDNA genome is 
encapsidated by the icosahedral nucleocapsid, which is comprised of 7-12 highly ordered proteins 
with a symmetrical organization, except for the portal which lies at one vertex [12].  Surrounding 
this is a proteinaceous tegument layer that contains proteins involved in entry and egress of the 
capsid, viral transport, virion assembly, and transcriptional regulators of both viral and cellular 
genes that promote a lytic infection [13].  The outer layer is a host-derived lipid envelope that is 
studded with viral glycoproteins.  The viral proteins on the outer envelope are involved in binding 
to cells and fusion with the target cell membrane, resulting in viral entry.   
1.1.2  VZV latency 
The defining characteristics of all alphaherpesviruses is a specific genomic arrangement, a 
short reproductive cycle, the ability to replicate in a variety of tissues and cells, and the 
establishment of latency from which virus can reactivate.  Most, but not all, alphaherpesviruses 
establish latency in sensory neurons.   It has been proposed that VZV latency in humans should be 
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defined as the persistence of non-productive repressed viral genomes that can reactivate.   This 
true reactivation can sometimes be confounded by abortive infections in which viral genomes 
merely persist due to the host cell’s lack of ability to allow lytic replication [14].   
VZV is an exclusively human-specific virus causing human disease only.  One of the issues 
with VZV biology is that there are currently no animal models that recapitulate the full spectrum 
of VZV disease, including the induction of a reactivatable latent state.  The only models that might 
apply are the guinea pig, which can host some VZV replication; and a parallel model in monkeys 
with simian varicella virus (SVV), which is the most related virus to human VZV.  There exists, 
however, a human embryonic stem cell (hESC)-derived neuron platform that has proven to be 
successful in modeling VZV latency and reactivation [15].  This model, and one like it, closely 
follows the general mechanism of establishing latency as seen with human disease.  That is, virus 
can infect at the axon tips of neurons and travel by retrograde axonal transport to the cell body, or 
soma.  In human infections, the onset of latency is promoted by infection at the axon termini.  
During entry into the axons, the tegument proteins are left behind at the fusion point as the virus 
travels down the axon.  As a result, tegument protein transactivators are not delivered to the nucleus 
[16-18].  Once in the soma the virus becomes quiescent, or latent, and the genome is maintained 
in an episomal state.  This silenced chromatin state is suspected to be maintained by many host 
cell mechanisms, including the actions of histone deacetylases (HDACs) and phosphatidylinositol-
3-kinase (PI3K)-induced signaling pathways.  HDACs act to silence gene expression by 
deacetylation, which promotes a latency-favorable environment.  Persistent PI3K signaling from 
receptor binding by nerve growth factor (NGF) aids in maintaining this latent state.  
Experimental latency can also be established by infecting neurons directly with cell-free 
VZV but with the addition of antiviral drugs, which are used to block initiation of lytic infections.  
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In such infections the outcome is often a mixture of virus that establishes a latent state upon 
infection and virus that initiates a lytic infection, which, if left unchecked will take over the culture 
[19].  A commonly used class of antiviral drugs, known as nucleoside analogs, can promote 
herpesvirus latency by interfering with DNA replication in lytic infections.  These drugs are similar 
enough to nucleotides that they are preferentially incorporated into the viral genome during DNA 
replication, but in doing so they result in a chain termination.  In published studies, the nucleoside 
analog acyclovir (ACV) has been most often used but VZV is considerably more resistant to ACV 
when compared to HSV.  One other compound our lab has been exploring is brivudine (BVDU), 
a nucleoside analog of thymidine that is specifically activated upon phosphorylation by the viral 
thymidine kinase (TK), but not human TK [20].  This drug is far more effective against VZV than 
ACV and thus is the antiviral we use to establish latency. 
It is thought that because the virus is prevented from replicating its DNA, it becomes 
silenced by chromatin so that a latent state is established immediately upon infection.  Infected 
neurons can also detect viral nucleic acids via innate sensors and secrete non-cytolytic type I 
interferon (IFN-I) and proinflammatory cytokines in response, which may inhibit lytic viral 
replication and promote latency in the local environment.  The presence of virus-specific T-cells 
in VZV-infected ganglia suggests that the actions of the innate and adaptive cellular immune 
system are controlling the latent state [21].  Furthermore, studies using fetal human dorsal root 
ganglia (DRG) xenografts transplanted in severe combined immunodeficient (SCID-hu) mice 
suggests that the VZV infectious process can be modulated solely by innate responses since the 
animals do not have an adaptive immune response [22]. 
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1.1.3  Reactivation from latency 
Full reactivation can be defined as the molecular switch from the repressed viral state to a 
lytic replication cycle which results in infectious progeny virus.  Reactivation in humans is a 
complex process that is heavily regulated by several cellular factors as well as immunological 
mechanisms.  The in vitro reactivation process is a simplified adaptation of some of the key factors 
involved in maintaining the latent state.  This is highlighted by the lack of any type of immune 
control in in vitro latency experiments.  However, it is worth considering some of the factors that 
are thought to regulate reactivation of herpesviruses.   
Briefly, one of the more currently accepted models of HSV reactivation involves a two-
stage reactivation program [23].  To review, latency is established in nuclei of infected neurons 
when viral genomes are heavily chromatinated, silencing viral IE gene expression.  
Chromatinization involves wrapping the viral DNA around histones forming nucleosomes, which 
play an important role in both transcriptional activation and repression.  Because neurons are non-
dividing, the cells remain alive and the viral genomes are maintained in a silent state.  Phase I, or 
animation, is initiated when neuronal stress response pathways are activated, which in turn 
activates the c-Jun N-terminal kinase (JNK) pathway by other cellular mediators.  This results in 
the phosphorylation of histones, leading to derepression of the genome which allows chromatin to 
become more permissive for transcription.  A general burst of viral IE, E, and L gene transcription 
results in de novo synthesis of several viral proteins.  The transcription of viral genes during phase 
I does not follow the widely accepted cascade of viral gene expression seen in acute lytic 
infections.  Repressive viral factors and/or innate immune responses may also be triggered during 
this phase, in which case the viral genome will be silenced, and latency is established once again.  
If sufficient quantities of key viral proteins are made during phase I, a second wave of viral gene 
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expression occurs (phase II, or reactivation) in the typical cascade of gene expression, which 
results in the amplification of viral DNA and assembly of infectious virus.  This two-stage 
reactivation model for HSV can theoretically be applied to VZV.  This model further emphasizes 
why cellular immunity plays such an important role in preventing reactivation and HZ.      
Latent infections can be experimentally reactivated in in vitro cultures.  A common 
reactivation stimulus is the application of HDAC inhibitors, such as sodium butyrate (NaB), which 
reverses the silencing mechanism of HDACs, leading to hyperacetylation of histones.  This creates 
an environment that is more favorable for transcription in general, permitting the genome to be 
derepressed, leading to lytic replication, resulting in infectious virus particles [24].   
The repressive actions of PI3K signaling can also be reversed by the addition of the PI3K-
inhibitor LY294002 [25].  When NGF binds to its receptor TrkA it initiates cellular signaling 
through PI3-K which maintains chromatin repression states, therefore the addition of LY and/or 
NGF withdrawal should result in increased viral replication [15].  When switching to this 
permissive lytic state, histone acetyl transferases acetylate histones, which reduces their DNA 
binding and condensation.  This action reduces the repressive state of the genome and permits 
access by transcription factors and allows viral gene expression to proceed.  Some groups have 
also used an NGF-specific antibody to deplete the NGF in cultures to induce reactivation [26].  An 
issue is that this reduces the NGF signaling that is necessary to maintain the viability of the 
neurons.  
1.1.4   Challenges of working with VZV 
VZV infectivity is highly cell-associated and produces very little infectious extracellular 
virus in culture.  The basis of this has eluded investigators because fluid taken from varicella 
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lesions contain highly infectious cell-free virus.  When cells are lysed, infectious virus not only 
remains bound to membrane components, but also becomes unstable and loses titer rapidly.  
Cryopreservation of infectious virus stocks requires that all cells in the culture dish, infected and 
uninfected, are trypsinized and frozen as intact cells using classical cell freezing media containing 
10% DMSO.   This is unlike virus isolation from HSV infected cells, where large amounts of 
mature HSV virions are present in the cytoplasm of infected cells and are released from the infected 
cell into the media.  Harvesting high titer HSV only requires freeze/thaw cycles to lyse the cells, 
releasing even more virus into the media, with free virus preparations greater than 5 x 109 PFU/ml 
being easily obtained.  It is not known why the VZV infectious particle to virion ratio is extremely 
low (around 1 in 106), while for HSV it is around 1 in 100 [27].  A possible explanation is that in 
VZV, the envelope is acquired by budding through cellular vesicles that may be formed by the 
induction of the initial steps of autophagy [28].  While the freeze/thaw method will lyse the cells, 
the large amounts of virus bound to cellular membranes/debris presents challenges for any 
immunofluorescence studies, since these membrane components are often full of antigen.  While 
cell-free VZV preparations are possible, the methods are rather laborious and require large 
amounts of infected cell cultures which still yield very low and unstable titers.  Viral kinetics 
studies are difficult to assess because a synchronous infection cannot be performed since cell-free 
titers are rarely above 105/ml.  The virus particles in the infecting cells are at all stages of 
replication making it difficult to assess timing of viral kinetics.  Finally, high host cell specificity 
remains one of the major challenges of working with VZV in a laboratory setting.  While VZV in 
humans exhibits broad tissue tropism (epithelial, keratinocyte, T cell, sebocyte, monocyte, 
endothelial, Langerhans and PBMC) [29], the host cell range in the experimental setting is more 
restricted.   
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1.2 Neuron Model Systems 
1.2.1  hESC-derived neurons 
The use of hESC-derived neurons has become a critical tool in studying VZV latency and 
reactivation as they allow the study of VZV in its natural reservoir of latency, the human neuron.  
hESCs can be differentiated into any number of cell types provided the right signals for 
differentiation pathways are provided, but more specifically, a multitude of neuronal phenotypes 
have been developed by differentiation.  Neurons with characteristics of peripheral sensory 
neurons can be derived through this platform making them an ideal model for virus-neuron 
interaction studies including axonal transport [30].  However, the differentiation process gives rise 
to a heterogeneous neuron population (a mix of sensory and CNS-like neurons) which requires 
further investigation and careful identification of the desired peripheral neurons.  
1.2.2  Non-hESC derived neuron culture systems 
Excised human fetal ganglia offer a viable alternative platform for VZV studies, but many 
ethical issues exist along with the added challenge of obtaining fresh neuronal tissues for culture.  
While some studies have shown that VZV can propagate in these neurons in culture, latency and 
reactivation have not been convincingly demonstrated [31-33].  Alternatively, human cadaveric 
ganglia have been used to study some aspects of VZV latency.  Because much of the population 
has been previously infected with HSV and/or VZV, most of these ganglia may already harbor 
latent virus, making it difficult to establish a nascent infection in vitro.  These studies, however, 
have substantiated the presence of the VZV latency-associated transcript (VLT) and ORF63 
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transcripts in human latency [34], and moreover have shown that the latent genome is circular and 
episomal [35].  One aspect that has not yet been achieved with dissociated or intact cadaveric 
ganglia is reactivation of latent virus resulting in production of infectious virus [36].  
Neuron-like cells called SH-SY5Y have been derived from bone marrow biopsies from a 
neuroblastoma patient.  These cells can be terminally differentiated into neuron-like cells in which 
VZV replicates and exhibits intracellular spread [37], but a reactivatable latent infection has not 
been reported.  In addition, SH-SY5Y neurons lack many characteristics of mature adult human 
ganglionic neurons.  
Lastly, the SCID-hu mouse in vivo model which contains human fetal ganglia xenografts 
examines human neurons in a system in which glia and satellite cells can interact with the 
implanted ganglia to assess VZV pathogenesis [38, 39].  Studies have reported that VZV genomes 
have persisted in the xenografts for months, suggesting a latent infection has been established.  
However, to date, there have not been any reports of reactivation of VZV in these persistently 
infected grafts, leading to speculation that these could possibly be abortive infections.   It is clear 
that further expansion of this model is necessary to gain further knowledge into VZV 
neurotropism. 
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 Public Health Significance and Statement of Purpose  
While clinical manifestations of VZV disease have been reduced with the introduction of 
vaccines for both varicella and HZ, the incidence of VZV diseases, in particular HZ, is likely to 
persist for quite some time.  There are around a million cases of HZ each year in the US, with over 
one third becoming complicated by long term sequelae.  Most adults still harbor wild-type VZV 
in their ganglia with the potential to reactivate to cause HZ, and a lifetime risk of disease is 
estimated to be 20-35% [40, 41].  Both shingles vaccines have low coverage for multiple reasons.  
Increased disease risk and complications are ever-present in the immunocompromised/immune-
suppressed population including individuals with cancers or HIV/AIDS, transplant recipients on 
immunosuppressive therapies, and pregnant women.   While VZV does respond to antivirals, 
treatment must be initiated very rapidly after onset of rash to be effective.  As such, it is likely that 
HZ and its complications will be an important public health concern for years to come.   
While VZV lies dormant in the sensory ganglia of the host for life, we still know very little 
about the latent state of this virus.  We argue that knowledge of the latent state will permit us to 
identify targets during latency that can be eventually developed to prevent reactivation.   
A gap in our knowledge stems from the fact that the current hESC-neuron models of 
latency are still quite inefficient, and only a small fraction of neurons become latently infected 
[15]. This makes the analyses of whole latently infected neuron cultures difficult, because 
signatures from the few latent neurons are difficult to distinguish from the vast majority of 
uninfected neurons.  Our ultimate goal is to be able to compare the transcriptional events occurring 
in a latently VZV-infected neuron to those of uninfected neurons.  Are there specific subtypes of 
neurons that are preferentially infected like in many HSV models [42]?  Does latency influence 
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the host transcription program?  Can latently-infected neurons be selected and concentrated?  What 
does the VZV latent genome make during latency?   So far, latent genomes have been identified 
using fluorescence in situ hybridization (FiSH) [15], and for this system it requires cell fixation 
and isopycnic isolation of nuclei, followed by an extensive FiSH protocol.  That approach does 
not tell us much more than the fraction of neurons that are VZV positive and where the genome 
signature resides in the nucleus.  The first aim of this project seeks to overcome this knowledge 
gap by developing methods to directly label viral genomes.  The first approach was to test the 
possibility of labeling genomes in a live-cell environment which allows subsequent analyses of 
virus-host interactions.  The second method to detect viral genomes does require fixation of the 
cells, but all cellular structures remain intact and nuclei do not need to be isolated. 
The gap in knowledge for the second aim is that while we currently have utilized the hESC-
derived neuron platform to give us fairly pure human neuron populations, the methodologies 
employed in obtaining these neurons is quite tedious and time-consuming, and requires a high 
level of technical skill and expertise.  This model has taken us years to adapt and optimize, and 
while generating extensively large hESC-derived neuron cultures is not insurmountable, it is 
inefficient at best.  The second aim of this work sought to explore alternative neuronal model 
systems that are not only simpler to establish and expand, but also determine whether such systems 
are permissive for VZV and/or can host a model latent state of VZV and mirror the successes seen 
thus far with the hESC-derived neuron model.  This aim will also extend to assessing the ability 
to study viral latency and reactivation in this alternative model system. 
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 Specific Aims 
3.1 Aim 1:  Development of Methods to Identify VZV Genomes in Latently Infected Cells 
This aim sought to explore new methods to identify latent viral genomes in both infected 
cell cultures as well as neuron cultures.  Two different approaches were used to address this issue 
that involves both the live-cell environment as well as fixed cells. 
3.1.1  Aim 1A:  An approach for live-cell detection of viral genomes utilizing the tetO/TetR-
GFP system 
Few methods exist that will allow for detection of viral genomes in a latent infection due 
to the simple fact that during latency the virus becomes inactive and no longer makes detectable 
proteins or nascent genomes.  While viral proteins can be tagged with fluorescent proteins which 
allows for direct detection of live virus during a lytic infection, they are not made in detectable 
quantities once latency is established.  Moreover, identification of the infected cell becomes 
difficult while maintaining live cell status.   The approach was to develop a recombinant virus 
which employs the tetracycline operator/tetracycline-repressor (tetO/TetR) system.  This 
repressor-operator system has been used to visualize incoming HSV genomes by showing the close 
association of viral genomes with promyelocytic leukemia nuclear bodies (PML or ND10) and 
their development into discrete replication compartments [43].  In that report, the authors 
transfected an amplicon plasmid containing both the TetR and tetO elements and then infected 
with a helper HSV-1 virus to visualize the auto-fluorescent genomes.  The amplicon plasmid 
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contained viral packaging signals, a CMV promoter driving expression of EYFP or EGFP fused 
to a nuclear localization sequence and the TetR protein, an HSV-1 OriS replication origin, and 
tandem repeats of the tetO sequence.  The amplicon plasmid would only be replicated when the 
helper HSV-1 virus was present in the same nucleus, and the progeny HSV particles would contain 
the tandem tetO repeats and TetR protein.  Infectious virus particles harvested from these cells 
were used to infect new cells, and through time-lapse fluorescent imaging they were able to 
visualize the incoming viral genomes.  This provided the framework for us to exploit this system 
to visualize VZV genomes in living cells.  In the amplicon plasmid system, expression of the Tet 
components was transient.  For our purposes, however, we wanted to have both Tet components 
expressed in the VZV itself, negating the need for exogenous plasmids.   
The plan was to make a recombinant virus engineered to encode 112 tandem repeats of the 
tetO genetic elements, and that also expresses the TetR protein fused to GFP under a strong 
constitutive promoter.  The TetR-GFP encoded by the virus would not be part of the virion or its 
essential genes, so it should exist as freely diffusing protein within the infected cell.  The TetR-
GFP protein expression would be inserted at the VZV ORF2 and 3 intergenic region.  ORFs 2 and 
3 are transcribed in opposite directions to this region of interest, thus insertion of transgenes here 
will not affect any viral promoters.  The cassette containing 112 tandem copies of the tetO genetic 
element would be inserted at the large intergenic gap between ORF60 and 61, which would also 
not interfere with any viral promoters.  The rationale behind this system was that the free TetR-
GFP proteins will specifically bind to the tetO elements in the viral genome resulting in 
fluorescently labeled viral genomes that can be visualized in real-time lytic infections.  We 
hypothesized that while the virus itself would be shut down during latency, the TetR-GFP protein 
made from the strong constitutive CMV IE promoter should remain in the cell and bind to its 
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target, the tetO elements in the viral genome.  In effect we hoped this method would mirror the 
results obtained with FiSH, but theoretically label the genome in a live-cell environment that does 
not require any further manipulation or addition of extraneous reagents.   
3.1.2  Aim 1B:  Labeling of VZV genomes with click chemistry modifiable nucleotides 
In theory, the establishment of latent genomes in our hESC neuron system comes from the 
infecting virus, since lytic replication is prevented naturally (by infecting from axonal tips) [26] or 
by antivirals when the infection is initiated at the neuronal soma.  The logic of this approach was 
to use the thymidine analog 5-Ethynyl-2´-deoxyuridine (EdU), which is incorporated into 
replicating DNA in dividing cells and the replicating viral genome.  This method will be used to 
incorporate EdU into newly infected, replicating VZV-infected cell cultures so that virus progeny 
that is harvested (as well as uninfected cells) will all contain DNA with incorporated EdU.  
Infectious preparations of this EdU-labeled virus can then be used to infect new cells or neurons 
in which we experimentally induce latency.  The genomes that have incorporated EdU should be 
able to be detected by click chemistry.  While the method does involve fixation of the cells, it does 
maintain the cellular integrity of the neurons that FiSH does not yet provide.  
3.2 Aim 2:  Modeling Viral Latency and Reactivation Using Alternative Systems to hESC-
Derived Neurons 
The goal of this aim was to develop an alternative, and easily expandable, neuron culture 
system derived from a CNS neuronal cell line to use alongside the well-established hESC-derived 
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neuron culture system so that the biochemistry of latency be investigated.  This alternative platform 
involved the culturing of LUHMES cells and differentiating them into post-mitotic neurons to 
study neuronal latency, productive replication and reactivation in an easily scalable culture system. 
3.2.1  Aim 2A:  Establishing permissiveness of LUHMES cells to VZV infection 
A recent report has demonstrated that LUHMES-derived neurons are susceptible to HSV-
1 infection and can host a latent state that can be experimentally reactivated [44].  HSV-1 is a 
closely related alphaherpesvirus to VZV, but it has a very broad tropism, infecting most 
mammalian cells.  Therefore, our goal here is to model this recent success using VZV and 
extrapolating similar datasets exemplified with our hESC-derived neuron system.  However, VZV 
is more growth restricted compared to HSV and far fewer cell lines can host viral growth in vitro.  
Establishing that VZV can replicate in this cell line is paramount to proceeding with any further 
experiments.  We will first determine if mitotically active undifferentiated LUHMES cells can 
support a lytic VZV infection by utilizing fluorescently labeled VZV to monitor spread of virus 
between cells.  This can then be extended to the use of post-mitotic differentiated neurons derived 
from LUHMES cells to determine if a lytic infection can be initiated.  
3.2.2  Aim 2B:  Establishment of latency in LUHMES neurons 
Following up on the confirmation of lytic VZV infection, we will then seek to establish a 
latent infection in LUHMES neurons.  Initial experiments will utilize qPCR methods to 
differentiate latent from lytic genomes.  The native structure of the VZV genome in the virion and 
in the actively replicating lytic infected cell is predominantly a linear form.  During latency, the 
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VZV genome circularizes and becomes episomal by ligation of the genome ends.  In recent years 
qPCR methods have been developed that allow for the detection of and distinction between linear 
and circular viral genomes [26].  The method utilizes oligonucleotides specific for an internal 
region of the VZV genome (ORF49), which should yield a PCR product from all genomes; and 
oligonucleotides specific for fused genomic termini (TR), which should amplify quantifiable 
products only from cells in which the genome has circularized or has formed a concatemer.  
Absolute copy numbers determined from each of the reactions will be used to calculate the ratio 
of fused termini to internal viral sequences (TR/ORF49 ratio).  A ratio of 1 will mean there are 
equal levels of genomic forms, indicating that the virus is not actively replicating.    A ratio of less 
than one means that there are higher levels of linear genomes present than are circular forms, 
indicative of an actively replicating lytic infection.  It is important to note that circular genomes 
will also be present, albeit in much lower levels, during lytic infection due to the proposed rolling 
circle model of replication.   This method will be used not only to assess the validity of LUHMES 
neurons as a model for VZV latency and reactivation, but also to assess the ability of viral mutants 
with genes knocked out to establish latency in future experiments.  
Latent infections will be established using the antiviral compound brivudine to block lytic 
infections.  The qPCR data will confirm whether latent infections are supported by LUHMES 
neurons.  If these neurons can indeed support a latent infection, we can then assess whether the 
latent virus can be reactivated by using the HDAC inhibitor sodium butyrate and/or PI3K-inhibitor.   
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 Materials and Methods 
4.1 Cell Culture 
4.1.1  Standard cell culture 
All cells lines used were purchased commercially from ATCC unless otherwise noted and 
all culture media/reagents were purchased from Life Technologies unless otherwise stated.  MeWo 
and MRC5 cells were maintained in Minimum Essential Medium (MEM) supplemented with 10% 
fetal bovine serum (FBS) (Atlanta Biologicals) and Antibiotics/Antimycotics (Anti/Anti) solution 
consisting of 100 units/ml of penicillin, 100 µg/ml of streptomycin, and 0.25 µg/ml of 
amphotericin B.  Retinal pigmented epithelial (RPE) cells were maintained in Dulbecco's Modified 
Eagle Medium/Nutrient Mixture F-12 (DMEM/F-12) supplemented with 10% FBS and Anti/Anti.   
4.1.2  Viruses 
All viruses used were based on the VZV Parent of Oka (pOka), the clinical varicella isolate 
that was used as the basis for the varicella vaccine.  The VZV pOka genome was maintained in a 
bacterial artificial chromosome [17] which was manipulated using previously published 
markerless Red-recombination methods [45].  We discovered two mutations in the original pOka 
BAC which were corrected via Red-recombination (Yee and Kinchington, unpublished data).  This 
repaired construct served as the parental backbone for all subsequent recombinant virus generation.  
For generating recombinant viruses, 2.5 µg of purified BAC DNAs were transfected into MeWo 
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cells with Lipofectamine 3000 (Life Tech) along with 100 ng each of CMV61 and CMV62 plasmid 
DNAs.  VZV IE61 and IE62 are viral transcriptional transactivators that were cloned into 
expression plasmids under the constitutive CMV promoter.  The transient expression of these 
proteins aids in replication of the transfected viral genome, resulting in faster generation of 
infectious virus.  Without the addition of these plasmids, viral replication would initially be reliant 
solely on cellular transcription machinery.  Infected cell cultures showing 90% cytopathic effect 
(cpe) were mitotically inhibited by the addition of mitomycin C, to prevent cells from replicating, 
for 3 hours prior to harvesting the cells for cryopreservation.   
VZV with EGFP fused to the amino terminus of the late protein encoded by ORF23 was 
described previously [19].  Cell-free VZV was prepared as previously described [46].   
The parental plasmids containing TetR-GFP and the tetO repeat elements were a kind gift 
from Benedikt Kaufer (Free University of Berlin, Institute of Virology).  The BACs were 
maintained in an E. coli strain, known as GS1783, that contains chromosomally encoded Red- and 
I-SceI-expression under inducible promoters [47]. For the tetO/TetR-GFP genome tagging 
construct, a recombinant BAC was generated to contain mCherry fused to the small capsid protein 
encoded by ORF23, inserted with a removable kanamycin cassette that was subsequently removed.  
Next, the TetR-GFP sequence was inserted in the non-essential intergenic region between ORFs 2 
and 3 with a Zeocin (zeo) selection cassette.  We attempted to PCR amplify the entire multimeric 
tetO sequence with no success.  The tetO cassette was then removed from the parental plasmid, 
BB505, and sub-cloned into a pUC19 vector that contained homologous sequences to the 
intergenic region between ORFs 60 and 61 in the VZV genome, where we were inserting the 
cassette.  This vector was linearized and inserted into the parental BAC which contained mCherry-
ORF23 and the TetR-GFP-Zeo cassette.  A schematic of the construct is shown in Figure 1.  
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Purified BAC DNA was transfected, as mentioned above, to generate viruses which expressed 
TetR-GFP (VZV-mCherry-ORF23_TetR-GFP) and TetR-GFP/TetO (VZV-mCherry-
ORF23_TetR-GFP_TetO). 
 
Figure 1. Recombinant VZV Genome Schematic. 
4.1.2.1 EdU-labeling and detection 
RPE cells were infected with VZV.GFP-ORF23 and then incubated with 10 µM EdU for 
48 hours to allow for the replicating infected cells to uptake and incorporate the thymidine analog 
into the cellular and viral genomes.  When the cells were showing 90% cpe, mitomycin C was 
added to the cells for 3 hours and the cells were harvested and cryopreserved.  Virus stocks were 
then used to infect uninfected RPE or MRC5 cells or neurons.  Cells were fixed with 4% 
paraformaldehyde 24 hpi and the Click-iT Plus EdU Cell Proliferation Kit for Imaging, Alexa 
Fluor 555 dye (Life Tech.) kit was used to detect the EdU label following manufacturer’s protocol.   
4.1.3  Stem cell culture and differentiation into neurons  
The H9 human embryonic stem cells (hESCs, WiCell) were cultured using both feeder-
dependent and feeder-independent methods.  Feeder-dependent culture methods used ‘hESC 
Medium’ consisting of KnockOut™ DMEM/F-12 medium supplemented with GlutaMax 
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Supplement, 20% KnockOut™ Serum Replacement (KSR, Life Tech.), 1% non-essential amino 
acids (NEAAs), 20 ng/ml basic fibroblast growth factor (bFGF, Shenandoah Biotechnology) and 
100 µM 2-mercaptoethanol (2-ME, Life Tech.) and Anti/Anti.  Feeder-independent culture 
medium used was StemFlex™ Medium supplemented with StemFlex™ Supplement and 
Anti/Anti.  Following passage by either method, ROCK inhibitor Y-27632 was added to the culture 
media for 24 hours to increase cell survival rates.    
For feeder-dependent culture, γ-irradiated CF-1 mouse embryonic fibroblast (MEF) cells 
(Applied StemCell) were maintained in DMEM supplemented with 10% FBS, 1% NEAAs, and 
Anti/Anti.  MEFs were plated the day prior to initiating hESC co-cultures.  The H9 cells were 
thawed, briefly centrifuged at 850 rpm for 5 minutes, and resuspended in hESC Medium.  The H9 
cells were co-cultured with MEF cells in hESC medium with daily medium changes until 
homogeneous undifferentiated colonies were large enough to passage.  Colonies were manually 
dissected and dislodged from the monolayer under microscope in a laminar flow hood and 
passaged as clumps.   
Feeder-independent cultures were initiated on a 6-well dish pre-coated with GelTrex 
Basement Membrane Mix (Life Tech).  Colonies were passaged either by manual dissection or 
using ReLeSR™ Enzyme-free cell selection and passaging reagent (STEMCELL Tech.) per 
manufacturer’s instructions.   
To generate neural precursor cells (NPCs), H9 cells were co-cultured with the PA6 mouse 
stromal fibroblast cell line (RIKKEN BioResource Center).  The day prior to co-culture, dishes 
pre-coated with 0.1% Gelatin were seeded with PA6 cells in DMEM with 10% FBS, 1% NEAAs, 
and Anti/Anti.  Before addition of H9 cells, the PA6 cells were rinsed 3X with PBS to remove any 
residual FBS.  H9 cells were then co-cultured with PA6 cells in stromal-derived inducing activity 
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(SDIA) medium (Glasgow's MEM (GMEM) supplemented with 10% KSR, 1 mM sodium 
pyruvate, 1% NEAAs, 100 µM 2-ME, and Anti/Anti) for 10-14 days, with medium changes every 
third day.  NPC colonies were manually dislodged using a stereo dissecting microscope into the 
medium, centrifuged at 850 rpm for 5 minutes, and resuspended in Neurogenic Medium [48] 
(Neurobasal medium, B-27 Supplement, 10 ng/ml each of NGF, NT-3, and BDNF, and Anti/Anti) 
and transferred to low-adhesion suspension culture plates.  The NPCs were differentiated as 
floating spheres (neurospheres, NS) for 7-10 days.  The spheres were then added to culture dishes 
coated sequentially with Poly-D Lysine (PDL) and GelTrex and allowed to terminally differentiate 
for 10-14 days in Neuron Medium (Neurogenic Medium supplemented with CultureOne (Life 
Tech) to reduce the number of proliferating glial progenitors). 
4.1.4  LUHMES cell culture 
Undifferentiated Lund Human Mesencephalic (LUHMES) cells were cultured on dishes 
sequentially coated with poly-L-ornithine (PLO) and fibronectin or as 3D spheres in suspension 
culture dishes.  Basal medium for culture was Advanced DMEM/F-12 supplemented with N2 
Supplement (Life Tech.) and Anti/Anti.  For routine maintenance and passage of LUHMES cells 
in an undifferentiated state, basal medium was supplemented with 40 ng/ml bFGF.  Post-mitotic 
LUHMES cells were maintained on PDL-GelTrex coated culture dishes in basal medium 
supplemented with 1 µg/ml tetracycline or doxycycline, 1mM dibutyryl cyclic AMP (db-cAMP), 
2 ng/ml GDNF, 10µM Nardosinone, and Anti/Anti.   
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4.2 Microfluidics Devices 
We manufactured microfluidics devices with two compartments connected by micro 
channels.  We fabricated our own silicon-based master in cleanroom conditions.  In brief, silicon 
wafers (University Wafer) were spin-coated with SU-8 2002 Photoresist (Microchem) in a 2-step 
process and soft baked.  An array of microchannels (10-15 μm wide; 450 μm long; 2-2.5 μm high) 
was defined by UV light exposure and development of SU-8.  Standard soft lithography was 
performed using Sylgard 184 polydimethylsiloxane (PDMS; Dow Corning).  The SU-8/silicon 
master was first silanized to prevent PDMS from adhering to the master.  Because of the restrictive 
height (2.5 μm) in the channels, cells should be unable to migrate through the channels, but 
diffusion of small molecules is not impeded.  Schematics are shown in Figure 2. 
 
 
Figure 2. Dimensions of PDMS microfluidics devices and establishment of hydrostatic pressure gradient. 
Panel A shows the measurements of each channel (10 µm), the distance between each channel (30 µm), the distance 
between each cluster of 10 channels (130 µm), and the length of the channels from chamber to chamber (450 µm).  
The lighter gray boxes on either side of the channels represent the 150 µm “shelf” shown in B that allows the seeding 
of neurospheres close to the channels.  Panel B shows a cross-section of a PDMS device with the appropriate media 
levels to achieve the hydrostatic pressure gradient and measurements of channel and shelf heights. 
 24 
4.2.1  Axon isolation using microfluidics devices 
PDMS microfluidics devices were permanently bonded to glass substrates using a PE-25 
plasma cleaner (Plasma Etch).  PDMS and glass substrate were exposed to plasma for 2 minutes 
at a flow rate of 5 cc/min under 200 mTorr vacuum pressure and then the plasma-exposed surfaces 
immediately brought together.  The chambers of the devices were coated sequentially with PDL 
and GelTrex before the addition of cells to the “Soma” (cell-body) chamber of the device.   
For hESC-derived neurons, the medium for the Soma chamber is the same Neuron Medium 
formulation described previously.  The Axon medium uses the same Neuron Medium with 10-fold 
higher NGF concentration to attract axons from the Soma chamber to the Axon chamber.  
Neurospheres were seeded onto the Soma side close to the channels and filled with Soma medium 
to just under the top of the chamber (Figure 2B).  Axon medium was added to the axon chamber 
to a level that forms a bubble above the top of the chamber to create a dual hydrostatic pressure 
and NGF concentration gradient.  Axonal projections were allowed to extend through the micro 
channels and into the Axon chamber (7-14 days).   
For LUHMES-derived neurons, Soma medium was Advanced DMEM/F-12 with N2 
supplement, 1µg/ml doxycycline, 1mM db-cAMP, 2 ng/ml GDNF, 10µM Nardosinone, and 
Anti/Anti.  The medium for the Axon compartment was the same formulation but with 10-fold 
higher concentrations of doxycycline, db-cAMP, GDNF, and Nardosinone.  
4.2.1.1 Retrograde axonal infection 
Once axons have projected into the Axon chamber, mitotically inhibited cell-associated or 
cell-free VZV was added to the Axon compartment.  At this stage the pressure gradient was 
switched to the Soma side (i.e. higher medium level in Soma compartment) to further prevent the 
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possibility of free virus or cell debris from flowing through the channels and into the Soma 
chamber.  The NGF gradient was also removed so that both chambers contained the same medium 
with the same concentration of growth factors.  Latent infections in the neuron soma should be 
established by at least 14 dpi following axonal infection [15].   
4.3 Immunofluorescence and Microscopy 
Cell monolayers (RPE or MRC5) to be analyzed were washed with PBS without calcium 
and magnesium  (Ca++Mg++), fixed in 4% paraformaldehyde (PFA) for 20 minutes, washed in 
PBS, permeabilized with 0.2% Triton X-100 for 5 minutes, and blocked for at least one hour in 
10% heat-inactivated goat serum (HIGS).  Neurons to be analyzed were washed with PBS 
containing Ca++Mg++, fixed for 30 minutes in 4% paraformaldehyde, washed in PBS without 
Ca++Mg++, and permeabilized with 0.5% Triton X-100/1% Tween-20 in PBS for 2 x 10 minutes.  
Permeabilized cells were then blocked in 10% (HIGS) in PBS for at least one hour.  All antibody 
incubations were performed in 10% HIGS.  Primary antibodies used were rabbit anti-VZV-IE62 
and anti-VZV-ORF29 (produced in-house); mouse antibodies to VZV ORFs 29 and 62 (Center for 
Proteomics, University of Rijeka); chicken anti-beta tubulin III (Novus Biologicals); rabbit anti-
Brn3A and mouse anti-GFAP (EMD Millipore); and rabbit anti-peripherin (Neuromics).  All 
secondary antibodies used were produced in goats and conjugated to Alexa Fluor dyes (Life 
Tech.).  Nuclei were visualized by incubating with the DNA-binding dyes Hoechst 33342 or DAPI 
(Life Tech.). 
Images were taken on an Olympus Fluoview 1000 line scanning confocal microscope and 
analyzed using Fiji image analysis software. 
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4.4 DNA/RNA Isolation and Quantitative PCR 
4.4.1  DNA and RNA isolation for detection of VZV genomes 
Cells were harvested for DNA and RNA simultaneously using the Quick-DNA/RNA 
Miniprep Kit (Zymo Research) following the manufacturer’s protocol.   
4.4.2  qPCR for VZV DNA configuration 
VZV-pOka BAC DNA in which the viral genomic termini are fused was used as a control 
for episomal (circular) viral DNA.  DNA isolated from cell-free VZV-pOka was used to determine 
copy numbers for linear viral DNA without fused termini.  Primers used in this work are listed in 
Table 1.  Real-time qPCR was performed using PowerUp™ SYBR™ Green Master Mix with a 
StepOnePlus™ Real-Time PCR System (Applied Biosystems™).  Primers directed to ORF49 
were used to determine copy number of linear viral genomes.  Episomal DNA was measured using 
primers directed to the terminal fusion region.  VZV-pOka BAC DNA was used to generate a 
standard curve for circular genomes.  DNA isolated from cell-free VZV-pOka was used to generate 
a standard curve for linear genomes.  The ratio of the absolute copy number of viral PCR products 
amplified from termini primers to internal primers was calculated.  Absolute copy number was 
determined based on standard curves derived from 101 to 106 copies of full-length VZV-pOka 
BAC DNA.  The qPCR conditions were as follows:  50°C for 2 minutes, 95°C hot start for 5 
minutes; 45 cycles of 95°C for 15 seconds, 58°C for 10 seconds, and 72°C for 45 seconds.  
Dissociation curve analysis from 60 to 95°C was performed after every qPCR run to exclude 
nonspecific amplification and formation of primer-dimers. 
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Table 1.  qPCR primers used for viral DNA configuration. 
Target Primer Sequence 
ORF49 (putative late) 
ORF49-F21 5′- CGG TCG AGG AGG AAT CTG TG - 3′ 
ORF49-R80 5′- CCG TTG CAC GTA ACA AGC TC - 3′ 
Fused termini 
T1 5′- AGT GTC TGT CTG TCT GTG CG - 3′ 
T2 5′- CGC GGG TTT TGT TAA AGG CT - 3′ 
4.5 Southern Blot  
The parental plasmid BB505, which contains the tetO cassete, and genomic DNA isolated 
from MeWo cells in which BB505 was transfected, were digested with two restriction 
endonucleases (REs), XhoI and Tth111I and separated by gel electrophoresis.  BAC DNA isolated 
from bacteria and genomic DNA (gDNA) isolated from VZV-infected cells was also digested with 
the same enzymes and run on the same gel as the control.  The agarose gel containing the DNA 
fragments was denatured in a solution of 1.5M NaCl/0.5M NaOH at pH 13, neutralized in a 
solution of 1.5M NaCl/1M Tris-HCl at pH 7.5, and transferred by capillary action in a high salt 
buffer (20X SSC) to a highly-positively charged nylon membrane.  The membrane was cross-
linked using a Stratagene Stratalinker UV-Crosslinker, blocked, and probed with an oligo specific 
to the tetO sequence labeled with an infrared dye (5’-IRDye800).  Following several stringency 
washes, the membrane was imaged using a Li-Cor Odyssey Infrared Imaging System.     
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 Results 
5.1 Aim 1:  Development of Methods to Identify VZV Genomes in Latently Infected Cells 
5.1.1  Aim 1A:  An approach for live-cell detection of viral genomes utilizing the tetO/TetR-
GFP system 
Tandem repeats of tetO elements are unstable in BAC and VZV constructs. 
Generating and characterizing the tetO/TetR-GFP virus proved to be very difficult and 
time-consuming.  Several sub-cloning intermediates were necessary to ensure the tetO insert 
contained the proper homology arms to recombine into the pOka BAC.  In our initial approach, 
we inserted the tetO-kan-in cassette into the parental BAC (already containing mCherry-ORF23) 
first, followed by removal of the kan cassette.  Then we recombined in the TetR-GFP-kan-in 
cassette.  We encountered issues getting the TetR-GFP-kan-in cassette to recombine into the BAC, 
so we re-engineered the cassette to encode for the non-removeable Zeocin resistance gene instead 
of kan.  Restriction length polymorphism (RFLP) analysis confirmed the insertion of both the tetO 
and TetR-GFP mutations based on known sequences and expected fragment sizes, and viable virus 
was generated from the BAC.  During lytic infection of MRC5 cells we observed TetR-GFP signal 
primarily localized in the nucleus (Figure 3A), as expected, where the viral DNA containing the 
tetO elements is replicated and maintained.  However, we did not observe TetR-GFP signal 
localizing to the sub-nuclear replication compartments as expected.  Treatment of the cells, before 
and after infection, with the antivirals acyclovir (ACV) and Cidofivir (CDV) should prevent viral 
replication, thus driving the virus into a quiescent state where the genomes will be localized in 
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sub-nuclear compartments.  While the latency-like conditions closely reflected this expected 
localization, the diffuse nuclear GFP signal (Figure 3B) should have diminished, leaving only few 
GFP puncta as has been observed with FiSH [15].  Because this expected phenotype was not 
observed (even out to 120 hpi), we further analyzed these constructs by Southern blot with a tetO- 
sequence-specific probe.  The results of the Southern blot indicated that the inserted repeats were 
not the correct length (Figure 4).  The restriction enzyme (RE) XhoI (fragments outlined in red) 
was chosen because it cuts in the 95bp spacer sequence between 6 tandem tetO elements, resulting 
in multiple 347bp fragments (Figure 4, indicated above genome schematic).  The 7kb fragment 
from VZV.mCh23_TetO_TetR represents the genomic region preceding the start of the tetO 
cassette plus the first 6 tandem repeat sequences.  However, the 347bp fragments are barely 
detectable in both the BAC DNA and viral genomic DNA (gDNA), suggesting that the tetO 
sequences were largely deleted.  Although the input levels of BAC plasmid DNA appear quite low 
in the XhoI lane, the lack of 347bp fragments still indicates that the sequences were deleted in the 
bacterial clone before virus was generated.  The Tth111I RE (fragments outlined in black) was 
chosen because it digests at either end of the entire 112-tandem repeat sequence (indicated below 
the genome schematic).  In the parental plasmid, there is only one site for Tth111I which should 
result in linearization of the DNA, and as such only a single band should be present.  However, 
this 11.6kb expected fragment is degraded to several smaller fragments.  Digestion of the 
recombinant BAC and VZV-infected cell gDNA with Tth111I should have resulted in a 9.7kb 
fragment, but this was reduced by about 4.5kb in the BAC and by 5.5kb in the virus.  Because 
recombination was induced to remove the kan-cassette from the tetO cassette, and a second time 
to insert the TetR-GFP-Zeo fragment, we speculated that the large tetO cassette may have been 
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subjected to too many rounds of recombination to generate the dual-expression virus resulting in 
large deletions.   
We then generated a second dual-expression virus, but this time the TetR-GFP-Zeo cassette 
was inserted first.  Because the zeo cassette was not removeable, there was only a second round of 
recombination induced to insert the tetO-Kan-in.  The kan-in cassette was in-frame with the rest 
of the genome sequences and did not interfere with the tetO sequences, so another recombination 
event was not necessary to remove the kan.  RFLP analysis again confirmed the correct size 
fragments were present in the BAC DNA (Figure 5A), and viable virus was generated from this 
construct.  Southern blotting of the new construct revealed that the tetO cassette remained intact 
in the BAC DNA this time, but the virus generated from the BAC again deleted a large portion of 
the tandem repeats (Figure 5B).  The Tth111I digest confirms the full-length tetO cassette was 
maintained in the BAC DNA, but around 4kb of the tetO sequence was deleted in the virus.  
Although equivalent amounts of all DNAs were digested, the signal levels of the parental plasmid 
BB505 digests were not as strong as the previous blot suggesting some technical discrepancies.  
Immunofluorescence staining was performed on MRC5 cells infected with the TetR-GFP single 
expression virus (Figure 3C), which displayed expected generalized GFP signal since the TetR-
GFP protein does not have a specific target to bind to.  MRC5 cells infected with the new dual-
expression virus were probed for the VZV ORF29 protein (Figure 3D).  The protein encoded by 
ORF29 is a single-stranded DNA (ssDNA) binding protein that has been found in human ganglia 
harboring latent VZV genomes [49], and is predominantly localized to the nucleus of infected cells 
in vitro  as it is closely associated with the viral genome during replication [50].  We expected to 
see co-localization of TetR-GFP with the ORF29 protein, however, they appeared to juxtapose one 
another in the nucleus.  It appears that the TetR-GFP protein is being sequestered into sub-nuclear 
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compartments, and it doesn’t seem to associate directly with the other viral proteins.  We speculate 
that perhaps some tetO elements are still intact in the viral genome, but there may be too few of 
them to produce visible GFP foci or they might be deleted or degraded in such a way that the TetR-
GFP protein doesn’t recognize them.  
  These results indicate that the repeat elements are unstable in both the bacteria and the 
virus.  The repetitive sequences are likely being degraded or deleted due to homologous 
recombination in both the bacteria and in mammalian cells.  While it may appear that this is not a 
viable method for tagging latent genomes in live cells, further development is necessary.  
 
Figure 3. Cellular localization of TetR-GFP and in infected MRC5 cells. 
MRC5 cells were infected with the first version of the dual-expression virus (A and B) and with the second version 
of virus expressing TetR-GFP alone (C) and expressing both TetR-GFP and tetO elements (D) and fixed at 48 hpi. 
(A) Lytic infection shows primarily nuclear localization of TetR-GFP with some cytoplasmic distribution.  (B) 
Experimental latency-like infection displays strictly nuclear distribution with several distinct foci within the nucleus.  
(C) Cells infected with virus expressing only the TetR-GFP without tetO showing generalized GFP signal.  (D) Cells 
infected with dual-expression virus displayed juxtaposing GFP and ORF29 localizations.  Nuclei were 
counterstained with DAPI and are displayed as either white or blue.  Images taken 40X (A, B, & D) and 20X (C).  
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Figure 4. Southern blot of BAC and VZV genomic DNA reveals that the tetO DNA repeat elements are 
unstable. 
 
The genome schematic does not display the entire VZV genome, only the regions that are pertinent to the Southern 
blot.  The numbers in the blue boxes represent the ORFs in the genome and the blue tick marks and numbers below 
the genome indicate relative sizes and do not correspond to their position in the genome.  XhoI cut sites are 
indicated above the genome in red text and Tth111I cut sites are indicated below the genome in black text.  The 
Southern blot represents cropped sections of the full blot for simplification.  A 42 base oligo probe with a 5’-
IRDye800 label was used to detect tetO sequences.  BB505 is the parental plasmid containing the tetO-Kan-in 
cassette.  Red boxes indicate XhoI fragments containing tetO sequences.  Black boxes indicate Tth111I fragments 
containing tetO sequences.  Asterisks (*) denote expected DNA fragment sizes and are color coded for the indicated 
RE. 
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Figure 5.  RFLP analysis and Southern blot of new dual-expression BAC DNA. 
(A) BAC DNAs were digested with BglII restriction enzyme and separated on a 0.8% agarose gel followed by 
staining with ethidium bromide (EtBr).  Lane M contains the molecular weight standards, with the numbers to the 
left representing DNA size in kilobases (kb).  Lane 1 represents the parental BAC containing mCherry-ORF23.  
Lane 2 is the parent with the recombined TetR-GFP-Zeo fragment.  The parental band just above 2kb (marked by a 
white asterisk) is shifted up to about 5kb with the addition of TetR-GFP-Zeo.  Lane 3 is mCherry-ORF23_TetR-
GFP-Zeo with the tetO-Kan-in cassette inserted (presence of 12kb fragment).  (B) Southern blot of parental plasmid, 
BAC DNA and gDNAs.  Plasmid/BAC DNAs are represented by P and gDNAs are represented by G.  The red 
boxes indicate the correct, expected XhoI fragments except that there were no 347bp fragments in the viral DNA.  
The asterisk indicated the expected size of the viral DNA Tth111I fragment that was reduced in the generation of the 
virus. 
 
 
 34 
5.1.2  Aim 1B:  Labeling of VZV genomes with click chemistry modifiable nucleotides 
Incorporation of EdU allows visualization of viral genomes by fluorescence microscopy.  
Another alternative method to FiSH we wanted to investigate was click-labeling of VZV-
infected cell viral genomes labeled with EdU.  During DNA replication, DNA polymerase 
incorporates the thymidine analog EdU, which contains a small alkyne modification that allows 
the chemical addition of an azide fluorophore by a copper catalyst.  The copper-catalyzed reaction 
itself is toxic to cells due to the formation of reactive oxygen species (ROS) [51], so this method 
requires fixation before click-labeling.  There are copper-free systems available for use in live 
cells, but currently they are only for the labeling of proteins and not nucleic acids.   We initially 
encountered some issues with this method using the standard Click‐iT® Edu Imaging Kit (Life 
Technologies) because even with fixation, the ROS generated during copper-catalyzed labeling 
reaction denatures GFP and thus diminishes its fluorescent signal [52].  We then used a newer 
version of the imaging kit (Click‐iT® Plus Edu Imaging Kit) which does not affect GFP signal.  
Our approach was to infect cells with EdU-labeled virus stocks and fix cells at various timepoints 
to visualize transfer of EdU-labeled genomes into new cells.   
 Uninfected MRC5 cells were seeded onto 2-well glass chamber slides.  The following day 
the cells were infected with 250 pfu of VZV.GFP-ORF23 labeled with EdU.  In a separate chamber 
the same infection was performed in the presence of phosphonoacetic acid (PAA), which inhibits 
viral DNA polymerase and thus synthesis of viral DNA [53].  Under these conditions with PAA, 
we would expect to see GFP-ORF23 only in the input cells because de novo infection can only 
progress up until DNA synthesis.  IE62 is made early in infection and thus is made even in the 
absence of DNA synthesis, so cells that express the EdU-555 and IE62 are newly infected cells.  
The cells were fixed at 24 hpi.  Following fixation of the samples and click-labeling of incorporated 
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EdU, the cells were stained with an antibody to the VZV IE62 protein and nuclei were 
counterstained with DAPI and analyzed by immunofluorescence. 
Untreated, newly infected cells showed general nuclear, as well as some subnuclear, 
labeling of DNA with EdU-555 as well as viral IE (IE62) and L (ORF23) proteins (Figure 6A).  
The arrow indicates a newly infected cell that is adjacent to what we presume to be an input cell 
that is positive for GFP-ORF23, EdU-555, and IE62.  At this timepoint, we would expect to see 
de novo infections that are positive for EdU and the IE62 protein.  The lack of GFP-ORF23 in the 
indicated cell suggests that the protein has not yet been expressed in the newly infected cell.  We 
also observed what we presume to be a third round of infection.  That is, a cell that is expressing 
only IE62 adjacent to a cell in which GFP-ORF23, EdU-555, and IE62 are all expressed suggests 
that these infections have lost the EdU label following multiple rounds of DNA replication (Figure 
6B, yellow arrows).  PAA-treated, infected cells displayed punctate EdU-555 signal and positive 
staining for IE62, but not ORF23 (which is only made following DNA synthesis), suggesting that 
we are observing de novo infection of a new cell and not an infecting cell from the inoculum 
(Figure 6C).  The presence of PAA allows for direct transfer of virus from the infecting cell to an 
uninfected cell, but will not produce new virus beyond this due to the inhibition of viral DNA 
polymerase [23].   
This data supports click chemistry detection of EdU-labeled VZV genomes as an 
alternative method to FiSH in productive infections in standard cell culture.  Ongoing studies will 
assess this method in both lytic and latent infections in neuron cultures. 
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Figure 6. MRC5 cells infected with VZV.GFP-ORF23 labeled with EdU. 
MRC5 cells infected with EdU-incorporated  VZV-GFP-ORF23 were fixed at 24 hpi.  EdU was labeled with click-
chemistry and cells were stained for IE62 and nuclei counterstained with DAPI.  (A) Cells lacking GFP signal but 
with positive staining for EdU and IE62 indicates a newly infected cell.  Images taken with 40X oil-immersion 
objective.  (B) Cells expressing only VZV IE62 adjacent to cells expressing GFP-ORF23, EdU555, and IE62 
suggests infection beyond initial viral replication.  (C) Cells were pre-treated with PAA for 2 hours prior to infection 
and maintained throughout.  This magnified nucleus shows a newly infected cell that lacks the late protein GFP-
ORF23 but positive for the IE62 protein and EdU label as small puncta, suggesting the virus is sequestered in 
replication compartments.   
5.2 Aim 2:  Modeling Viral Latency and Reactivation Using Alternative Systems to hESC-
Derived Neurons 
VZV causes several diseases involving the CNS, including meningitis, acute disseminated 
encephalomyelitis (ADEM), vasculopathies and increased risk of stroke [54], all of which 
underscore the relevancy of using the CNS-derived LUHMES cell line in our studies.  LUHMES 
cells remain proliferative through tetracycline-regulated (Tet-off) constitutive v-myc expression 
[55].  The v-myc promoter can be switched off upon the addition of tetracycline (or its synthetic 
 37 
derivative doxycycline), dibutyryl-cyclic AMP (db-cAMP), and glial cell-derived neurotrophic 
factor (GDNF) to the media.  At this stage the cells stop proliferating and begin to differentiate 
into post-mitotic neurons [56].  Before assessing permissiveness of LUHMES to VZV infection, 
we first characterized differentiated LUHMES neurons by immunofluorescence analysis.  IF 
images revealed positive staining for beta-III (βIII) tubulin (a marker for differentiated neurons) 
and, surprisingly, the presence of the mature peripheral sensory neuron markers peripherin and 
Brn3a in differentiated LUHMES (Figure 7).  While peripherin is expressed primarily in sensory 
neurons of the peripheral nervous system (PNS), it is also expressed in some neurons of the central 
nervous system (CNS) [57].   
       
Figure 7.  Differentiated LUHMES cells express markers for mature sensory neurons. 
LUHMES cells were terminally differentiated for 10 days before being fixed with 4% paraformaldehyde and stained 
with antibodies to beta-III tubulin (A and B), peripherin (A), Brn3a (B), and the nuclear counterstain DAPI (A and 
B). 
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5.2.1  Aim 2A:  Establishing permissiveness of LUHMES cells to VZV infection 
Both undifferentiated and differentiated LUHMES cells are permissive for VZV lytic 
infection. 
Before assessing the viability of using LUHMES neurons as a model for VZV latency and 
reactivation studies, we first needed to establish that these cells can support a lytic VZV infection.  
We first evaluated undifferentiated LUHMES cells for viral spread by infecting cell colonies with 
a cell-free preparation of the fluorescent reporter virus VZV.GFP-ORF23.  Phase-contrast and 
fluorescence live-cell images were captured from 24 hpi until 8 dpi (Figure 8A).  The spread of 
fluorescence from the initial foci seen at 24 hpi is indicative of lytic viral replication.  
Next, we differentiated LUHMES cells into post-mitotic neurons for 7 days.  Neurons were 
infected with cell-free VZV.GFP-ORF23 and phase-contrast and fluorescence live-cell images 
were captured from 24 hpi until 8 dpi (Figure 8B).  Again, the spread of fluorescence in the non-
dividing neurons indicates a lytic viral infection.   
In a separate experiment, LUHMES cells were differentiated for 49 days before infection 
with a cell-free preparation of VZV.  At 6 dpi, the neurons were fixed and stained for the viral 
IE62 protein and βIII tubulin.  Many neurons were positive for both markers (Figure 9).   
Together, these data provide evidence that LUHMES cells and neurons can support a 
productive VZV lytic infection with cell-free VZV.   
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Figure 8.  Both undifferentiated and differentiated LUHMES cells support a lytic VZV infection. 
Undifferentiated colonies of LUHMES cells (A) and post-mitotic LUHMES neurons (B) were infected with cell-free 
VZV.GFP-ORF23 and imaged every 24 hours until 8 dpi.  Images taken at 10X magnification. 
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Figure 9.  LUHMES neurons are permissive for VZV infection. 
LUHMES cells were terminally differentiated for 49 days and then infected with cell-free VZV.  At 6 dpi, the cells 
were fixed with 4% paraformaldehyde and stained with antibodies to VZV IE62, β-III tubulin, and DAPI. Images 
taken at 20X. 
 
5.2.2  Aim 2B:  Establishment of latency in LUHMES neurons 
LUHMES neurons can host a reactivatable latent VZV state.  
To assess the viability of using LUHMES neurons to model VZV latency and reactivation, 
LUHMES cells were plated on 2 coated 12-well dishes and allowed to proliferate overnight.  The 
following day, the media was changed to differentiation medium and the cells were maintained in 
this medium for 7 days, with media changes every other day.  Four wells of one plate were left 
uninfected, and the remaining neurons were infected with a cell-free preparation of VZV-pOka 
 41 
diluted 1:10 in culture medium both in the absence and presence of the antiviral brivudine 
(BVDU).  Virus was adsorbed for 2 hours at 37oC, washed with PBS, and culture medium was 
maintained as follows:  4 wells uninfected, standard medium; 4 wells pOka, standard medium; 16 
wells pOka in the presence of 2 µM BVDU (pOka+BVDU) (Figure 10).  Media was changed every 
third day until 7dpi, at which point Plate 1 (uninfected wells, pOka wells, 4 wells of pOka+BVDU) 
was harvested for DNA and RNA.  At 8 dpi BVDU was removed from the media in Plate 2 and 
changed to differentiation medium plus the following:  4 wells no addition; 4 wells add 4µM 
sodium butyrate (NaB); 4 wells add 10 µM PI3K-Inhibitor (PI3K-i) LY294002.  Media conditions 
were maintained for an additional 7 days, with media changes every third day until 14 dpi, at which 
point cells were harvested for DNA and RNA.  Identical experiments were set up with hESC-
derived neurons as positive controls. 
 
Figure 10.  Plate setup for lytic and latent infection experiments. 
Media conditions and infections are described in text.  Plate 1 was harvested for DNA and RNA at 7 dpi.  At 8 dpi, 
media was changed on plate 2 (dashed outline) to the appropriate conditions indicated on the far right diagram.  At 
14 dpi, plate 2 was harvested for DNA and RNA. 
 
Real-time qPCR was performed on 100 ng of each DNA sample.  The ratios of absolute 
copy numbers of the terminal region to ORF49 are shown in Figure 11.  Values greater than or 
equal to 1 indicate a latent infection because there are more circular genomes present than linear 
genomes.  Values closer to 0 indicate that there are more linear genomes present than there are 
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circular, signifying a lytic infection.  We expected to see no amplification from the uninfected cells 
from either primer set as they are virus specific.  We expected to see ratios closer to 0 for the 
infected-only cells because the virus is actively replicating.  For the infections in the presence of 
BVDU, we expected to see ratios ≥ 1 because the genomes should be circularized due to the 
prevention of viral replication.  We expected to see values closer to 0 in the samples where BVDU 
was removed and reactivation was stimulated by the addition of NaB or PI3K-i.  The data obtained 
from the LUHMES experiments (Figure 11B) met these expectations and mirrored results seen 
with hESC-derived neurons (Figured 11A).  This provided evidence that a latent infection can be 
established in LUHMES-derived neurons that can be experimentally reactivated to produce a lytic 
infection.    
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Figure 11.  Ratios of absolute copy numbers of terminal joint region to ORF49. 
Absolute copy numbers were calculated for each sample amplifying from the terminal joint region (TR) and from 
the internal ORF49.  Panel A contains data from hESC-derived neurons and panel B contains data from 
differentiated LUHMES neurons.  The ratio of TR/ORF49 for each condition was calculated and graphed.  Data 
shown is from 2 independent experiments, each with 4 replicates per condition for a total of N=8 replicates per 
condition.  There was no amplification from the uninfected samples and were thus omitted for simplicity.  
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LUHMES neurons generate extensive neurites that can be isolated using microfluidics 
devices.   
In parallel experiments, both hESC neurons and LUHMES cells were seeded in the Soma 
chamber of a microfluidics device and allowed to differentiate into neurons and extend neurite 
processes through the microchannels for 21 days.  Mitotically inhibited, cell-associated EdU-
labeled-VZV.GFP-ORF23 was then added to the axon chamber of the device and incubated for 14 
days.  The cells were then analyzed by immunofluorescence microscopy following click-chemistry 
labeling of the neuron soma.  We were able to detect few EdU-specific foci in the nuclei of some 
hESC neurons (Figure 12A) and LUHMES neurons (Figure 12B).  While latent infections should 
have theoretically been established at 14 dpi, the presence of the viral proteins ORF23 and IE62 
indicate otherwise.  They should only be expressed during a lytic infection.  Regardless, this data 
further supports utilizing LUHMES neurons in axon-isolation infections.  Ongoing experiments 
will address the appropriate timeframe at which VZV establishes a latent infection in the absence 
of antivirals.  We will also utilize BVDU to establish latent infections in upcoming experiments, 
and we will then assess whether we can reactivate these latent infections to induce lytic replication 
to generate infectious virus.      
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Figure 12.  EdU-labeled VZV genomes present in neuronal soma following axonal infection. 
(A) HESC neurons and LUHMES neurons (B) were seeded in the Soma chambers of microfluidics devices and 
differentiated for 21 days.  The axon chambers were infected with cell-associated mitotically inhibited EdU-labeled 
VZV-GFP23.  The Soma chambers were fixed at 14 dpi, followed by click labeling, immunofluorescence staining 
for VZV IE62, and nuclear counterstain with Hoechst 33342.  In the two-color panels, IE62 is magenta, however to 
allow for distinction between magenta and red, IE62 is pseudocolored gray in the four color merged images.  Images 
were taken at 40X magnification with an air objective. 
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 Discussion 
While our attempts to label VZV genomes in live cells utilizing VZV co-expressing both 
the tetO genetic elements and the TetR-GFP protein were not as successful as we had hoped, this 
fluorescent repressor-operator system of tagging viral genomes has been shown in adenovirus [58] 
and other herpesviruses ([43] and B. Kaufer, personal communication).  Both prokaryotic and 
eukaryotic cells possess mechanisms to eliminate repeated DNA sequences, which may explain 
the difficulties we experienced in generating the tetO/TetR-GFP construct.  Other researchers have 
circumvented this repair mechanism by inserting unique spacer sequences between multimers of 
the tetO elements, thereby reducing the chances of the repeated sequences being eliminated from 
the genome [59].  This approach may improve the system in our hands in the future.  However, we 
will proceed with the caveat that there still exits the potential for chromosome rearrangements 
between the repetitive homologous sequences [60].    In latency experiments, it is possible that the 
TetR-GFP protein may not be able to access the tetO elements due to chromatinization of the 
genome.  Another possible locus in the VZV genome for inserting the tetO cassette would be in 
the ORF61-62 region.  It is in this region that the VZV VLT was identified [34], suggesting that 
perhaps this region is not silenced by chromatin, or at least not to a large extent.  Although the 
Southern blot results suggest that about half of the repeat elements were deleted, perhaps there are 
enough genetic elements remaining to pursue this method further in ongoing neuron latent 
infections.  It might also be more beneficial to place the TetR-GFP expression under an inducible 
promoter, such as the tetracycline promoter, so that the TetR-GFP protein is only made under 
specified conditions.   
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Labeling of HSV genomes with ethynyl-modified nucleosides coupled with click-
chemistry has proven to be an invaluable tool to track viral genomes as well as identify proteins 
associated with the viral genome [61, 62].  In our hands, this method has allowed us to visualize 
viral genomes during lytic, and possibly latent, VZV infections.  The presence of viral proteins in 
neurons that were EdU-positive indicates that we may not have established a latent infection, even 
after the assumed 14-day induction of latency.  Further optimization is necessary to continue to 
explore the latent state in more detail.  If we can achieve this, we would also like to develop studies 
with both hESC-derived and LUHMES neurons in which we can identify cells harboring latent 
viral genomes and isolate them through laser-capture microdissection.  The goal of these studies 
would be to analyze the host and viral mRNA transcripts to better understand the cellular and/or 
viral factors involved in establishing and maintaining latency, and the requirements for inducing 
reactivation.  It is possible that we can utilize isolation of proteins on nascent DNA (iPOND) in 
conjunction with EdU/click-chemistry to demonstrate these interactions without the need for laser 
capture microdissection. 
The field of VZV latency and reactivation continues to be of great interest to researchers 
around the world.  While an in vivo model system would greatly substantiate in vitro data, there is 
no viable option that can adequately model all aspects of the VZV life cycle and disease.  While 
the hESC-derived neuron model system has allowed us to successfully model the lytic cycle of 
VZV infection as well as a reactivatable latent infection, reactivation in these neurons is inefficient.  
LUHMES cells have been widely used for neurotoxicity studies [63] and to study 
neurodegenerative diseases, such as Parkinson’s disease [64].  In addition, a recent study has 
demonstrated that LUHMES neurons can support a latent HSV-1 infection that can be reactivated 
[44], and as an extension possibly other neurotropic viruses.  This evidence validates exploring the 
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LUHMES neuron system further for studying VZV infections.  In this work, we have successfully 
demonstrated an alternative to the hESC-neuron model system with the ability to study both the 
lytic and latent cycle of VZV infection and reactivation.  While the results of the experiments 
shown here demonstrate that LUHMES can be highly permissive to lytic replication, the results of 
reactivatable latent infection are still preliminary.  We plan to perform more extensive qPCR 
analyses to further solidify this model for latency/reactivation studies.  We have obtained RNA 
from the same samples in which we obtained the gDNA used in the qPCR studies.  Ideally, these 
can be reverse transcribed into cDNA and analyzed for kinetic class transcripts as well as the VZV 
VLT, which would allow for the differentiation between and characterization of lytic and latent 
infections. 
The LUHMES neuron system is a more attractive platform for studying VZV for several 
reasons.  Initiating studies with hESCs is an expensive undertaking which entails obtaining 
approval to work with them.  The purchase price of one vial of hESCs is about 3-4 times as much 
as common cell culture lines and they are only available from select vendors.  LUHMES cells, 
however, are commercially available without restriction and can be propagated rather easily.  The 
specialized training that is required to culture hESCs took several months to develop in our lab, 
and some level of spontaneous differentiation of the cultures remains unavoidable.  Expansion of 
co-cultures to generate large numbers of hESC-neurons is an incredibly tedious and time-
consuming process.  On the other hand, scaling up of LUHMES cells is relatively simple as they 
are maintained using standard cell culturing methods and proliferate rapidly.  Biochemical and 
molecular assays which require high cell numbers, including assessment of chromatin changes, 
may be obtainable with the ease of scalability of LUHMES cells.  The timeline for differentiation 
into mature neurons is also more rapid with the LUHMES model (5-7 days vs. 14-28 days for 
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hESCs).  They are also cultured as single cells which makes the differentiated neurons easier to 
image by microscopy, unlike the difficulties faced when imaging large dense 3D spheroid 
structures of hESC-derived neurospheres.  Previous reports have rarely shown survival of 
LUHMES neurons beyond 21 days, while mature hESC-derived neurons have been shown to 
survive for up to 5 months in culture [65].  However, in this body of work, we have found 
LUHMES neurons can remain viable in culture for at least 55 days.  Long-term latency studies in 
these neurons are the next logical step for future experiments.   
This system may not be a direct substitution for the hESC-derived neuron model in all 
cases, as there are many unanswered questions with LUHMES neurons.  Can infected LUHMES 
neurons generate the VZV VLT RNA?  Do LUHMES neurons demonstrate comparable VZV 
axonal transport efficiencies as hESC neurons?  The neuronal phenotypes of differentiated 
LUHMES neurons needs to be further evaluated as well.  Thus far we have qualitatively identified 
the presence of peripherin and Brn3a, both markers of peripheral sensory neurons, in LUHMES 
neurons, but the number of neurons expressing these markers have not yet been quantified.  In 
hESC-derived neurons, it is estimated that only around 10% of neurons are peripherin and Brn3a 
positive [19].  In both systems, there are very few glial fibrillary acidic protein (GFAP) positive 
glial cells, suggesting that our differentiation protocols are perhaps selectively enhancing survival 
of non-dividing neuronal cells over proliferating non-neuronal cells.  Though these different 
neurons represent two different branches of the nervous system, the differentiation phenotypes are 
quite similar.  This is also pertinent to the fact that VZV can infect ganglia in both the PNS and 
CNS.  An interesting direction for future work would be to extend these LUHMES neuron studies 
in a more physiologically relevant system involving myelinated axons.  It has been demonstrated 
that hESCs can be differentiated into Schwann cells that, when co-cultured with isolated axons, 
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form a myelin sheath around the axons [66].  Schwann cells play an important role in nerve 
development and regeneration, presentation of antigens to T-lymphocytes, and are also permissive 
to VZV infection [67].  Utilizing our microfluidics devices in the generation of myelinated axons 
in vitro may help to advance the knowledge of VZV immunobiology without the need for 
expensive SCID-hu mouse experiments. 
Further experiments are planned to explore reactivation of latent VZV resulting in 
production of infectious virus.  This approach will involve using the microfluidics chamber system 
to isolate the axons from the soma in LUHMES and hESC neurons.  The neuron soma will be 
infected with fluorescent cell-associated VZV or cell-free VZV in the presence of brivudine so 
that lytic replication cannot occur in the neuronal nuclei.  Neurons will be maintained under these 
media conditions for 14 days, at which point uninfected RPE cells will be seeded in the axon 
chamber so that the cells will make direct contact with the axons.  Brivudine will be removed from 
the soma media and either NaB or PI3K-i, or both, will be applied to the soma compartment.  This 
should release the repressed viral genome and allow for lytic replication.  If infectious virus is 
generated, it should travel by anterograde axonal transport to the axon chamber where the virus 
will infect the RPE cells.  Presence of fluorescent RPEs in the axon chamber would indicate 
successful, true reactivation.  Success in this area would open the door for the electrophysiological 
study of soma and/or axon fusion.  Our lab is also investigating a method that may induce 
immediate latent infections in neurons.  This method employs a degron system in which we exploit 
the destabilizing domain of the E. coli dihydrofolate reductase (DHFR).  In this method, a protein 
that is fused to DHFR becomes unstable, signaling the ubiquitin-dependent proteasomal pathway 
(UPP) for poly-ubiquitination of the protein fusion and trafficking to the proteasome for 
degradation [68].  However, in the presence of trimethoprim (TMP), a small-molecule ligand, the 
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destabilizing domain is stabilized, preventing signaling of the UPP and the resultant proteasomal 
degradation.  Of importance, the stabilizing action of TMP is dose-dependent, fully reversible, 
generally non-cytotoxic, and has a much greater affinity for bacterial DHFR over eukaryotic 
DHFR.   Our approach would be to tag a VZV protein that is essential for viral replication.  We 
have developed a VZV in which the essential gene product of ORF4 is fused with DHFR and is 
tightly regulated by TMP (Ben Warner, unpublished data).  Utilizing our microfluidics devices, 
we can infect neuronal axons with this virus in the absence of TMP.  The virus will still be able to 
infect the axons and travel to the soma because functional ORF4 will still be packaged in the virion 
tegument, but lytic replication should not occur since any de novo ORF4 protein that is made will 
be immediately degraded.  In theory the virus should immediately establish a latent infection and 
should be reactivatable by induction with NaB and/or PI3K-I plus the addition of TMP to allow 
ORF4 to be stably expressed again.  There are other essential viral proteins we can explore with 
this method and we can potentially combine the DHFR method with our viral genome tagging 
strategies.   
Shingles is still a relevant public health concern in our modern society despite the advent 
of 2 different vaccines to prevent the disease from occurring.  There are also limited model systems 
in which researchers can employ to study the full infection and disease caused by VZV.  Our goal 
is to develop a more physiologically relevant system in which to study the latent infection and 
reactivation process so that we may help to advance insight into not only the VZV research field 
but other neurotropic virus research as well.  
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